Roche Diagnostics is at the forefront of diagnostic certainty, empowering oncology decision-making with our VENTANA portfolio.
We help our customers improve and grow by offering a wide range of high-quality medical tests and digital solutions while advancing science with the largest menu of assays, including companion diagnostics and digital pathology.
Our unique synergy between pharmaceuticals and diagnostics seamlessly pushes the frontiers of innovation; we are passionate about advancing oncology diagnostics for people with cancer.
Join us at USCAP 2024 to learn how pathologists and the labs they serve can rely on us.
Scientific workshops
Advancements in digital pathology
Baltimore Convention Center, Seminar Room 2
Monday, March 25 from 5:30 - 7 p.m. EST
Learn about the state of digital pathology today and the innovations that will lead us into the future.
Part 1: Digital Pathology – Today and into the Future. Mike Rivers, Roche global lifecycle leader for digital pathology, will address the unmet needs driving digital pathology adoption and the challenges that impede adoption.
Part 2: The Role of Primary Diagnosis in Digital Pathology. Keith Wharton, M.D., medical affairs lead for Roche Molecular Systems, will share updates regarding the state of primary diagnosis in digital pathology
Part 3: Advancements in HER2 Quantitative Image Analysis in the HER2-low Era. Audrey Bennett, M.D., pathology liaison for Roche Diagnostics’ medical and scientific affairs, will explore the role of AI with a focus on advancements in HER2 quantitative image analysis in the HER2-low era and how AI algorithms can provide objective and reproducible assessments while minimizing subjectivity.
Current and emerging biomarkers in gastric cancers
Baltimore Convention Center, Seminar Room 2
Monday, March 25, noon - 1 p.m. EST
Testing provides more insight into locally advanced or metastatic G/GEJ adenocarcinomas as more biomarkers are discovered. Routine IHC staining methods utilize emerging and established biomarkers, and evolving guidelines for G/GEJ adenocarcinomas support using biomarkers to help improve identification of these tumors and map a path forward for patients.
Anthony M. Magliocco, M.D., founder and CEO of Protean BioDiagnostics, will explain these developments and help participants confidently navigate the rapidly changing landscape of established and emerging biomarkers such as CLDN18 and FGFR2b in mGastric/GEJ cancers based on data from several Phase 3 clinical trials.
Lunch will be provided.
